Evidence map›Paper›PMID 31035476›Full record

ArticleViruses2019

In Depth Breadth Analyses of Human Blockade Responses to Norovirus and Response to Vaccination.

Joel Haynes, Virginia Perry, Evelyn Benson, Alisa Meeks, Gayle Watts, Heather Watkins, Ralph Braun

Abstract read
In one paragraph

Article in Viruses, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Virus-Host Interactions Between Nonsecretors and Human Norovirus.Cellular and molecular gastroenterology and hepatology · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Joel HaynesVaccines Discovery Research, Takeda Pharmaceuticals, Cambridge, MA 02139, USA. joelroberthaynes@gmail.com.
Virginia PerryVaccines Discovery Research, Takeda Pharmaceuticals, Cambridge, MA 02139, USA. rideskiclog@gmail.com.
Evelyn BensonVaccines Discovery Research, Takeda Pharmaceuticals, Cambridge, MA 02139, USA. evelyn.benson1@montana.edu.
Alisa MeeksVaccines Discovery Research, Takeda Pharmaceuticals, Cambridge, MA 02139, USA. alisa.meeks@gmail.com.
Gayle WattsVaccines Discovery Research, Takeda Pharmaceuticals, Cambridge, MA 02139, USA. wa7@msn.com.
Heather WatkinsVaccines Discovery Research, Takeda Pharmaceuticals, Cambridge, MA 02139, USA. heather.watkins@takeda.com.
Ralph BraunVaccines Discovery Research, Takeda Pharmaceuticals, Cambridge, MA 02139, USA. ralph.braun@takeda.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To evaluate and understand the efficacy of vaccine candidates, supportive immunological measures are needed. Critical attributes for a norovirus vaccine are the strength and breadth of antibody responses against the many different genotypes. In the absence of suitable neutralization assays to test samples from vaccine clinical trials, blockade assays offer a method that can measure functional antibodies specific for many of the different norovirus strains. This paper describes development and optimization of blockade assays for an extended panel of 20 different norovirus strains that can provide robust and reliable data needed for vaccine assessment. The blockade assays were used to test a panel of human clinical samples taken before and after vaccination with the Takeda TAK-214 norovirus vaccine. Great variability was evident in the repertoire of blocking antibody responses prevaccination and postvaccination among individuals. Following vaccination with TAK-214, blocking antibody levels were enhanced across a wide spectrum of different genotypes. The results indicate that adults may have multiple exposures to norovirus and that the magnitude and breadth of the complex preexisting antibody response can be boosted and expanded by vaccination.

Indexed as

VaccinationAntibodies, ViralAntibody FormationCaliciviridae InfectionsClinical Trials as TopicGastroenteritisGenotypeHumansImmunoassayNorovirusVaccines, Virus-Like ParticleViral VaccinesAntibodies, ViralVaccines, Virus-Like ParticleViral VaccinesblockadenorovirusvaccineVLP

Identifiers

PMID31035476
PMCPMC6563306

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.